BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 25531544)

  • 1. Secondary antifungal prophylaxis in hematological malignancy patients with previous invasive fungal disease: a retrospective analysis.
    Liu M; Li Y; Zhang Y; Zhao X; Zhai B; Zhang Q; Wang L; Zhao Y; Li H; Wang Q; Gao C; Huang W; Yu L
    PLoS One; 2014; 9(12):e115461. PubMed ID: 25531544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study.
    Sun Y; Meng F; Han M; Zhang X; Yu L; Huang H; Wu D; Ren H; Wang C; Shen Z; Ji Y; Huang X
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1117-26. PubMed ID: 25840339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Secondary antifungal prophylaxis in hematological malignancy patients with previous invasive fungal disease].
    Liu MJ; Huang WR; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Apr; 23(2):596-600. PubMed ID: 25948232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination antifungal treatment for invasive fungal disease after hematopoietic stem cell transplantation in children with hematological disorders.
    Qiu KY; Liao XY; Fang JP; Xu HG; Li Y; Huang K; Zhou DH
    Transpl Infect Dis; 2019 Jun; 21(3):e13066. PubMed ID: 30859662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis.
    Montesinos P; Rodríguez-Veiga R; Boluda B; Martínez-Cuadrón D; Cano I; Lancharro A; Sanz J; Arilla MJ; López-Chuliá F; Navarro I; Lorenzo I; Salavert M; Pemán J; Calvillo P; Martínez J; Carpio N; Jarque I; Sanz GF; Sanz MA
    Bone Marrow Transplant; 2015 Nov; 50(11):1465-72. PubMed ID: 26281032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of invasive fungal disease after unmanipulated haploidentical stem cell transplantation was significantly higher than that after HLA-matched sibling transplantation.
    Sun Y; Xu L; Liu D; Zhang X; Han W; Wang Y; Chen H; Chen Y; Wang F; Wang J; Ji Y; Tang F; Liu K; Huang XJ
    Clin Microbiol Infect; 2013 Nov; 19(11):1029-34. PubMed ID: 23565830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for recurrence of invasive fungal infection during secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients.
    Liu F; Wu T; Wang JB; Cao XY; Yin YM; Zhao YL; Lu DP
    Transpl Infect Dis; 2013 Jun; 15(3):243-50. PubMed ID: 23496156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Posaconazole oral suspension for secondary antifungal prophylaxis in allogeneic stem cell transplantation recipients: a retrospective study.
    Ye P; Pei R; Hu Y; Chen D; Li S; Cao J; Li F; Wu M; Fang Y; Lu Y
    BMC Infect Dis; 2022 May; 22(1):465. PubMed ID: 35570276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antifungal agents for secondary prophylaxis based on response to initial antifungal therapy in allogeneic hematopoietic stem cell transplant recipients with prior pulmonary aspergillosis.
    Liu Q; Lin R; Sun J; Xiao Y; Nie D; Zhang Y; Huang F; Fan Z; Zhou H; Jiang Q; Zhang F; Zhai X; Xu D; Wei Y; Song J; Li Y; Feng R
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1198-203. PubMed ID: 24769013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of long-term and short-term administration of itraconazole for primary antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell transplantation: a multicenter, randomized, open-label trial.
    Lin R; Xu X; Li Y; Sun J; Fan Z; Jiang Q; Huang F; Zhou H; Nie D; Guo Z; Mao Y; Xiao Y; Liu Q
    Transpl Infect Dis; 2014 Apr; 16(2):286-94. PubMed ID: 24593273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Granulocyte-Macrophage Colony-Stimulating Factor on Prevention and Treatment of Invasive Fungal Disease in Recipients of Allogeneic Stem-Cell Transplantation: A Prospective Multicenter Randomized Phase IV Trial.
    Wan L; Zhang Y; Lai Y; Jiang M; Song Y; Zhou J; Zhang Z; Duan X; Fu Y; Liao L; Wang C
    J Clin Oncol; 2015 Dec; 33(34):3999-4006. PubMed ID: 26392095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventing invasive fungal disease in patients with haematological malignancies and the recipients of haematopoietic stem cell transplantation: practical aspects.
    Akan H; Antia VP; Kouba M; Sinkó J; Tănase AD; Vrhovac R; Herbrecht R
    J Antimicrob Chemother; 2013 Nov; 68 Suppl 3():iii5-16. PubMed ID: 24155144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary antifungal prophylaxis: decrease of invasive fungal disease incidence and reduction of risk factors in haematological patients in a 5-year retrospective study.
    Li Y; Liu M; Zhai B; Zhao X; Wang L; Li H; Wang S; Zhu H; Wang Q; Gao C; Huang W; Yu L
    Intern Med J; 2018 Jun; 48(6):713-720. PubMed ID: 29230923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: a retrospective cohort study.
    Harrison N; Mitterbauer M; Tobudic S; Kalhs P; Rabitsch W; Greinix H; Burgmann H; Willinger B; Presterl E; Forstner C
    BMC Infect Dis; 2015 Dec; 15():584. PubMed ID: 26715563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical risk score for predicting invasive fungal disease after allogeneic hematopoietic stem cell transplantation: Analysis of the China Assessment of Antifungal Therapy in Hematological Diseases (CAESAR) study.
    Sun Y; Hu J; Huang H; Chen J; Li J; Ma J; Li J; Liang Y; Wang J; Li Y; Yu K; Hu J; Jin J; Wang C; Wu D; Xiao Y; Huang X
    Transpl Infect Dis; 2021 Aug; 23(4):e13611. PubMed ID: 33825274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry.
    Vehreschild JJ; Sieniawski M; Reuter S; Arenz D; Reichert D; Maertens J; Böhme A; Silling G; Martino R; Maschmeyer G; Rüping MJ; Ullmann AJ; Cornely OA
    Int J Antimicrob Agents; 2009 Nov; 34(5):446-50. PubMed ID: 19700265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Caspofungin as secondary antifungal prophylaxis and subsequent maintenance antifungal prophylaxis therapy in hematological malignancy patients.
    Liu M; Li Y; Zhao X; Zhang Y; Zhai B; Zhang Q; Wang L; Zhao Y; Li H; Wang Q; Gao C; Huang W; Yu L
    Int J Clin Exp Med; 2015; 8(7):11794-802. PubMed ID: 26380020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical investigation of reduced-dose voriconazole on primary prevention in invasive fungal disease after allogeneic hematopoietic stem cell transplantation].
    Qiu Z; Ren H; Cen X; Ou J; Xu W; Wang M; Wang L; Dong Y; Li Y; Liu W; Sun Y; Liang Z; Wang Q
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jul; 35(7):577-80. PubMed ID: 25052595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation: a 6-yr analysis from the cologne cohort for neutropenic patients.
    Vehreschild MJ; von Bergwelt-Baildon M; Tran L; Shimabukuro-Vornhagen A; Wisplinghoff H; Bangard C; Cornely OA; Vehreschild JJ
    Eur J Haematol; 2014 Nov; 93(5):400-6. PubMed ID: 24798021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fungal colonization of the respiratory tract in allogeneic and autologous hematopoietic stem cell transplant recipients: a study of 573 transplanted patients.
    Markowski J; Helbig G; Widziszowska A; Likus W; Kyrcz-Krzemień S; Jarosz U; Dziubdziela W; Markiewicz M
    Med Sci Monit; 2015 Apr; 21():1173-80. PubMed ID: 25907308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.